Propanc Biopharma, Inc.

PPCBdata completeness 63%17 fiscal years on file

Data notes: no data for concept 'revenue'

The thesis, from the filings

Propanc Biopharma, Inc. earns about -424% on equity, but has diluted owners by 31% over 5 years — worth asking whether the growth reaches owners. The cash-flow models don't apply cleanly here — the ledger says why below.Whether it’s worth owning at today’s price is the last question — and yours to answer, below.

i. The business — what you’d actually own

Figure	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025
Revenue	—	—	—	—	—
Net income	−$2.03M¹	−$2.66M²	−$2.66M³	−$1.82M⁴	−$58.9M⁴
Operating cash flow	−$1.15M⁵	−$1.44M⁶	−$1.11M⁷	−$935,118⁸	−$405,168⁸
Capital expenditure	—	—	—	—	—
Free cash flow (derived)	—	—	—	—	—
Total debt	$624,583⁹	$926,438¹⁰	$390,539¹¹	$399,325¹²	$537,921¹²
Cash & equivalents	$2,255¹³	$4,067¹³	—	—	—
Diluted shares	3.0M	68,219	1.7M	1,417	4.0M

Superscripts are receipts. Each links to the SEC filing the number came from (full list at the bottom).

ii. Your slice — ownership made literal

If you owned

Net assets behind them

$35.04

your share of equity

Profit it earned you last year

−$148.49

Free cash flow it threw off

—

Debt you’d be carrying

$1.36

10 shares is a claim on $35.04 of net worth that earned you −$148.49 last year, against $1.36 of debt.

iii. Is this a good business?

Moat signal · return on equity

-424% avg · 5y

FY21 —FY22 —FY23 —FY24 —FY25 -424%

It earned an average -424% on equity over 5 years. Compare that to what it costs to fund the business.

seeing a moat in the numbers →

Management signal · capital allocation

+31% shares · 5y

Share count is up 31% over 5 years — owners have been diluted. Worth asking what they got for it. Total debt has fallen 14% — deleveraging.

reading capital allocation →

Signals, not verdicts — read from the filings above. Numbers don’t prove a moat; they show its footprint. You decide.

iv. What it’s worth — engine v0.1.0

DCF · Growth Exit 10Y

not applicable

only 0 years of FCF (need ≥3) — model not applicable

DCF · Growth Exit 5Y

not applicable

only 0 years of FCF (need ≥3) — model not applicable

Earnings Power Value

not applicable

normalized (5y-median) earnings non-positive — EPV undefined

Graham Number

not applicable

diluted EPS missing or non-positive — Graham Number undefined

Different models answer different questions — which to trust when →

Sources — the receipts

10-K · period ending 2021-06-30 · accession 0001493152-22-027033 (NetIncomeLoss)
10-K · period ending 2022-06-30 · accession 0001493152-23-034632 (NetIncomeLoss)
10-K · period ending 2023-06-30 · accession 0001493152-24-038815 (NetIncomeLoss)
10-K · period ending 2024-06-30 · accession 0001493152-25-016069 (NetIncomeLoss)
10-K · period ending 2021-06-30 · accession 0001493152-22-027033 (NetCashProvidedByUsedInOperatingActivities)
10-K · period ending 2022-06-30 · accession 0001493152-23-034632 (NetCashProvidedByUsedInOperatingActivities)
10-K · period ending 2023-06-30 · accession 0001493152-24-038815 (NetCashProvidedByUsedInOperatingActivities)
10-K · period ending 2024-06-30 · accession 0001493152-25-016069 (NetCashProvidedByUsedInOperatingActivities)
10-K · period ending 2021-06-30 · accession 0001493152-22-027033 (LongTermDebt)
10-K · period ending 2022-06-30 · accession 0001493152-23-034632 (LongTermDebt)
10-K · period ending 2023-06-30 · accession 0001493152-24-038815 (LongTermDebt)
10-K · period ending 2024-06-30 · accession 0001493152-25-016069 (LongTermDebt)
10-K · period ending 2021-06-30 · accession 0001493152-22-027033 (CashAndCashEquivalentsAtCarryingValue)